Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK0626

Known as: MK-0626 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AIMS Exercise capacity is reduced in heart failure (HF) patients, due mostly to skeletal muscle abnormalities including impaired… Expand
Highly Cited
2015
Highly Cited
2015
Dipeptidyl peptidase-4 (DPP4) inhibitors used for the treatment of type 2 diabetes are cardioprotective in preclinical studies… Expand
2015
2015
Objective— Intestinal overproduction of atherogenic chylomicron particles postprandially is an important component of diabetic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Highly Cited
2015
Highly Cited
2015
Novel therapies are needed for treating the increasing prevalence of hepatic steatosis in Western populations. In this regard… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
BackgroundGlucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase-4 (DPP4) inhibitors are a newer class of antidiabetics… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2014
2014
AIM To investigate the mechanism and in vivo effects of MK-0626, a dipeptidyl peptidase-4 inhibitor, on hepatic steatosis using… Expand
2014
2014
Individuals with type 2 diabetes (T2D) are at greater risk of bone fractures than those without diabetes. Certain oral diabetic… Expand
2014
2014
Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic… Expand
2014
2014
Background Tacrolimus (TAC)-induced pancreatic islet injury is one of the important causes of new-onset diabetes in transplant… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2012
2012
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted into the circulation by the intestinal L cell. The… Expand